D.E. Shaw & Co
CRDF icon

D.E. Shaw & Co’s Cardiff Oncology CRDF Stock Holding History

D.E. Shaw & Co’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,806
Closed -$64K – 5392
2022
Q1 		$64K Buy
+25,806
New +$91.3K ﹤0.01% 5082
2021
Q1 		– Sell
-12,274
Closed -$221K – 4108
2020
Q4 		$221K Buy
+12,274
New +$216K ﹤0.01% 3705
2017
Q1 		– Sell
-250
Closed -$38K – 3332
2016
Q4 		$38K Buy
+250
New +$58.4K ﹤0.01% 3393
2016
Q3 		– Sell
-210
Closed -$68K – 3389
2016
Q2 		$68K Buy
+210
New +$72.3K ﹤0.01% 3278
2015
Q4 		– Sell
-176
Closed -$72K – 3814
2015
Q3 		$72K Sell
176
-863
-83% -$452K ﹤0.01% 3637
2015
Q2 		$759K Buy
+1,039
New +$737K ﹤0.01% 2896

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

D.E. Shaw & Co's CRDF Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Cardiff Oncology (CRDF) in Q2 2022, closing a stake of 25,806 shares — an estimated $64K sold.

D.E. Shaw & Co first reported a position in CRDF in Q2 2015 and held it in 6 quarters. The position peaked at $759K in Q2 2015. 67 funds tracked by Wall St. Rank hold CRDF as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Cardiff Oncology position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 25,806 Cardiff Oncology shares in Q2 2022, an estimated $64K.
  • D.E. Shaw & Co first reported a position in Cardiff Oncology in Q2 2015 and held it in 6 quarters.
  • D.E. Shaw & Co's Cardiff Oncology position peaked at $759K in Q2 2015.
  • 67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.